{
  "nct_id": "NCT03972488",
  "study_title": "Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET",
  "search_date": "2025-07-15T14:07:11.057044",
  "publications_found": 2,
  "publications": [
    {
      "pmid": "38851203",
      "title": "Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capde...",
      "authors": [],
      "journal": "From Clinical Trial Data",
      "year": "N/A",
      "doi": null,
      "abstract": "Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, Garcia-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D; all the NETTER-2 Trial Investigators. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024 Jun 29;403(10446):2807-2817. doi: 10.1016/S0140-6736(24)00701-3. Epub 2024 Jun 5.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38851203/",
      "source": "study_data"
    },
    {
      "pmid": "33973550",
      "title": "Jungels C, Deleporte A. State of the art and future directions in the systemic treatment of neuroend...",
      "authors": [],
      "journal": "From Clinical Trial Data",
      "year": "N/A",
      "doi": null,
      "abstract": "Jungels C, Deleporte A. State of the art and future directions in the systemic treatment of neuroendocrine neoplasms. Curr Opin Oncol. 2021 Jul 1;33(4):378-385. doi: 10.1097/CCO.0000000000000740.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33973550/",
      "source": "study_data"
    }
  ]
}